Download PDF
Semin intervent Radiol 2020; 37(05): 448-455
DOI: 10.1055/s-0040-1720950
Review Article

Treatment Options for Early-Stage Hepatocellular Carcinoma

Nora E. Tabori
1   Department of Radiology, Georgetown Medical School, Medstar Washington Hospital Center, Washington, District of Columbia
,
Gajan Sivananthan
1   Department of Radiology, Georgetown Medical School, Medstar Washington Hospital Center, Washington, District of Columbia
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Patients with early stage hepatocellular carcinoma have good prognosis and are treated with curative intent. Although this cohort of patients is generally defined by limited tumor burden, good liver function, and preserved functional status, there remains utility in further stratification to optimize overall survival and limit post-operative morbidity and mortality. Transplant, resection, ablation, transarterial radioembolization, and transarterial chemoembolization, either as monotherapy or in combination, may play a crucial role in treating this cohort of patients depending on a multitude of factors. In this section, we review each treatment modality and provide general guidelines for patient selection.

Keywords

Early stage hepatocellular carcinoma - transarterial radioembolization - transarterial chemoembolization - radiation segmentectomy - radiation lobectomy


Publication History

Article published online:
11 December 2020

© 2020. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19 (03) 329-338
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Mazzaferro V, Regalia E, Doci R. et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334 (11) 693-699
    CrossrefPubMedGoogle Scholar
  • 3 Mazzaferro V, Bhoori S, Sposito C. et al. Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. Liver Transpl 2011; 17 (Suppl. 02) S44-S57
    CrossrefPubMedGoogle Scholar
  • 4 Yao FY, Ferrell L, Bass NM. et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33 (06) 1394-1403
    CrossrefPubMedGoogle Scholar
  • 5 Yao FY, Xiao L, Bass NM, Kerlan R, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant 2007; 7 (11) 2587-2596
    CrossrefPubMedGoogle Scholar
  • 6 Parikh ND, Singal AG. Model for end-stage liver disease exception points for treatment-responsive hepatocellular carcinoma. Clin Liver Dis (Hoboken) 2016; 7 (05) 97-100
    CrossrefPubMedGoogle Scholar
  • 7 Heimbach JK, Hirose R, Stock PG. et al. Delayed hepatocellular carcinoma model for end-stage liver disease exception score improves disparity in access to liver transplant in the United States. Hepatology 2015; 61 (05) 1643-1650
    CrossrefPubMedGoogle Scholar
  • 8 Mehta N, Dodge JL, Goel A, Roberts JP, Hirose R, Yao FY. Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy. Liver Transpl 2013; 19 (12) 1343-1353
    CrossrefPubMedGoogle Scholar
  • 9 Yao FY, Mehta N, Flemming J. et al. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology 2015; 61 (06) 1968-1977
    CrossrefPubMedGoogle Scholar
  • 10 Oligane HC, Xing M, Kim HS. Effect of bridging local-regional therapy on recurrence of hepatocellular carcinoma and survival after orthotopic liver transplantation. Radiology 2017; 282 (03) 869-879
    CrossrefPubMedGoogle Scholar
  • 11 Gabr A, Kulik L, Mouli S. et al. 2020. ), Liver Transplantation Following Yttrium‐90 Radioembolization: 15‐year Experience in 207‐Patient Cohort. Hepatology. Accepted Author Manuscript.
  • 12 European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2018; 69 (01) 182-236
    CrossrefPubMedGoogle Scholar
  • 13 Park JW, Chen M, Colombo M. et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int 2015; 35 (09) 2155-2166
    CrossrefPubMedGoogle Scholar
  • 14 Wang MD, Li C, Li J. et al. Long-term survival outcomes after liver resection for binodular hepatocellular carcinoma: a multicenter cohort study. Oncologist 2019; 24 (08) e730-e739
    CrossrefPubMedGoogle Scholar
  • 15 Tsilimigras DI, Bagante F, Moris D. et al. Defining the chance of cure after resection for hepatocellular carcinoma within and beyond the Barcelona Clinic Liver Cancer guidelines: a multi-institutional analysis of 1,010 patients. Surgery 2019; 166 (06) 967-974
    CrossrefPubMedGoogle Scholar
  • 16 Yip VS, Poon RT, Chok KS. et al. Comparison of survival outcomes between right posterior sectionectomy and right hepatectomy for hepatocellular carcinoma in cirrhotic liver: a single-centre experience. World J Surg 2015; 39 (11) 2764-2770
    CrossrefPubMedGoogle Scholar
  • 17 Lee SY, Sadot E, Chou JF. et al. Central hepatectomy versus extended hepatectomy for liver malignancy: a matched cohort comparison. HPB (Oxford) 2015; 17 (11) 1025-1032
    CrossrefPubMedGoogle Scholar
  • 18 Kishi Y, Abdalla EK, Chun YS. et al. Three hundred and one consecutive extended right hepatectomies: evaluation of outcome based on systematic liver volumetry. Ann Surg 2009; 250 (04) 540-548
    CrossrefPubMedGoogle Scholar
  • 19 Shoup M, Gonen M, D'Angelica M. et al. Volumetric analysis predicts hepatic dysfunction in patients undergoing major liver resection. J Gastrointest Surg 2003; 7 (03) 325-330
    CrossrefPubMedGoogle Scholar
  • 20 Boleslawski E, Petrovai G, Truant S. et al. Hepatic venous pressure gradient in the assessment of portal hypertension before liver resection in patients with cirrhosis. Br J Surg 2012; 99 (06) 855-863
    CrossrefPubMedGoogle Scholar
  • 21 Teh SH, Christein J, Donohue J. et al. Hepatic resection of hepatocellular carcinoma in patients with cirrhosis: model of end-stage liver disease (MELD) score predicts perioperative mortality. J Gastrointest Surg 2005; 9 (09) 1207-1215 , discussion 1215
    CrossrefPubMedGoogle Scholar
  • 22 Cucchetti A, Ercolani G, Vivarelli M. et al. Impact of model for end-stage liver disease (MELD) score on prognosis after hepatectomy for hepatocellular carcinoma on cirrhosis. Liver Transpl 2006; 12 (06) 966-971
    CrossrefPubMedGoogle Scholar
  • 23 Abulkhir A, Limongelli P, Healey AJ. et al. Preoperative portal vein embolization for major liver resection: a meta-analysis. Ann Surg 2008; 247 (01) 49-57
    CrossrefPubMedGoogle Scholar
  • 24 Palavecino M, Chun YS, Madoff DC. et al. Major hepatic resection for hepatocellular carcinoma with or without portal vein embolization: perioperative outcome and survival. Surgery 2009; 145 (04) 399-405
    CrossrefPubMedGoogle Scholar
  • 25 Marti J, Giacca M, Alshebeeb K. et al. Analysis of preoperative portal vein embolization outcomes in patients with hepatocellular carcinoma: a single-center experience. J Vasc Interv Radiol 2018; 29 (07) 920-926
    CrossrefPubMedGoogle Scholar
  • 26 Wajswol E, Jazmati T, Contractor S, Kumar A. Portal vein embolization utilizing N-Butyl cyanoacrylate for contralateral lobe hypertrophy prior to liver resection: a systematic review and meta-analysis. Cardiovasc Intervent Radiol 2018; 41 (09) 1302-1312
    CrossrefPubMedGoogle Scholar
  • 27 Garlipp B, de Baere T, Damm R. et al. Left-liver hypertrophy after therapeutic right-liver radioembolization is substantial but less than after portal vein embolization. Hepatology 2014; 59 (05) 1864-1873
    CrossrefPubMedGoogle Scholar
  • 28 Vouche M, Lewandowski RJ, Atassi R. et al. Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection. J Hepatol 2013; 59 (05) 1029-1036
    CrossrefPubMedGoogle Scholar
  • 29 Teo JY, Allen Jr JC, Ng DC. et al. A systematic review of contralateral liver lobe hypertrophy after unilobar selective internal radiation therapy with Y90. HPB (Oxford) 2016; 18 (01) 7-12
    CrossrefPubMedGoogle Scholar
  • 30 Birgin E, Rasbach E, Seyfried S. et al. Contralateral liver hypertrophy and oncological outcome following radioembolization with 90Y-microspheres: a systematic review. Cancers (Basel) 2020; 12 (02) 294
    CrossrefPubMedGoogle Scholar
  • 31 Chen MS, Li JQ, Zheng Y. et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006; 243 (03) 321-328
    CrossrefPubMedGoogle Scholar
  • 32 Huang J, Yan L, Cheng Z. et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg 2010; 252 (06) 903-912
    CrossrefPubMedGoogle Scholar
  • 33 Feng K, Yan J, Li X. et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J Hepatol 2012; 57 (04) 794-802
    CrossrefPubMedGoogle Scholar
  • 34 Fang Y, Chen W, Liang X. et al. Comparison of long-term effectiveness and complications of radiofrequency ablation with hepatectomy for small hepatocellular carcinoma. J Gastroenterol Hepatol 2014; 29 (01) 193-200
    CrossrefPubMedGoogle Scholar
  • 35 Lee HW, Lee JM, Yoon JH. et al. A prospective randomized study comparing radiofrequency ablation and hepatic resection for hepatocellular carcinoma. Ann Surg Treat Res 2018; 94 (02) 74-82
    CrossrefPubMedGoogle Scholar
  • 36 Livraghi T, Goldberg SN, Lazzaroni S. et al. Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions. Radiology 2000; 214 (03) 761-768
    CrossrefPubMedGoogle Scholar
  • 37 Xu HX, Lu MD, Xie XY. et al. Prognostic factors for long-term outcome after percutaneous thermal ablation for hepatocellular carcinoma: a survival analysis of 137 consecutive patients. Clin Radiol 2005; 60 (09) 1018-1025
    CrossrefPubMedGoogle Scholar
  • 38 Cammà C, Di Marco V, Orlando A. et al; Unità Interdipartimentale Neoplasie Epatiche (U.I.N.E) Group. Treatment of hepatocellular carcinoma in compensated cirrhosis with radio-frequency thermal ablation (RFTA): a prospective study. J Hepatol 2005; 42 (04) 535-540
    CrossrefPubMedGoogle Scholar
  • 39 Poggi G, Montagna B, DI Cesare P. et al. Microwave ablation of hepatocellular carcinoma using a new percutaneous device: preliminary results. Anticancer Res 2013; 33 (03) 1221-1227
    PubMedGoogle Scholar
  • 40 Huo YR, Eslick GD. Microwave ablation compared to radiofrequency ablation for hepatic lesions: a meta-analysis. J Vasc Interv Radiol 2015; 26 (08) 1139-1146.e2
    CrossrefPubMedGoogle Scholar
  • 41 Liang P, Dong B, Yu X. et al. Prognostic factors for survival in patients with hepatocellular carcinoma after percutaneous microwave ablation. Radiology 2005; 235 (01) 299-307
    CrossrefPubMedGoogle Scholar
  • 42 Xu J, Zhao Y. Comparison of percutaneous microwave ablation and laparoscopic resection in the prognosis of liver cancer. Int J Clin Exp Pathol 2015; 8 (09) 11665-11669
    PubMedGoogle Scholar
  • 43 Zhang M, Ma H, Zhang J, He L, Ye X, Li X. Comparison of microwave ablation and hepatic resection for hepatocellular carcinoma: a meta-analysis. OncoTargets Ther 2017; 10: 4829-4839
    CrossrefPubMedGoogle Scholar
  • 44 Glassberg MB, Ghosh S, Clymer JW, Wright GWJ, Ferko N, Amaral JF. Microwave ablation compared with hepatic resection for the treatment of hepatocellular carcinoma and liver metastases: a systematic review and meta-analysis. World J Surg Oncol 2019; 17 (01) 98
    CrossrefPubMedGoogle Scholar
  • 45 Chong CCN, Lee KF, Chu CM. et al. Microwave ablation provides better survival than liver resection for hepatocellular carcinoma in patients with borderline liver function: application of ALBI score to patient selection. HPB (Oxford) 2018; 20 (06) 546-554
    CrossrefPubMedGoogle Scholar
  • 46 Oh IS, Sinn DH, Kang TW. et al. Liver function assessment using albumin-bilirubin grade for patients with very early-stage hepatocellular carcinoma treated with radiofrequency ablation. Dig Dis Sci 2017; 62 (11) 3235-3242
    CrossrefPubMedGoogle Scholar
  • 47 Wakuta A, Nouso K, Kariyama K. et al. Radiofrequency ablation for the treatment of hepatocellular carcinoma with decompensated cirrhosis. Oncology 2011; 81 (01) 39-44
    CrossrefPubMedGoogle Scholar
  • 48 Llovet JM, Vilana R, Brú C. et al; Barcelona Clínic Liver Cancer (BCLC) Group. Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. Hepatology 2001; 33 (05) 1124-1129
    CrossrefPubMedGoogle Scholar
  • 49 Jaskolka JD, Asch MR, Kachura JR. et al. Needle tract seeding after radiofrequency ablation of hepatic tumors. J Vasc Interv Radiol 2005; 16 (04) 485-491
    CrossrefPubMedGoogle Scholar
  • 50 Yu J, Liang P, Yu XL, Cheng ZG, Han ZY, Dong BW. Needle track seeding after percutaneous microwave ablation of malignant liver tumors under ultrasound guidance: analysis of 14-year experience with 1462 patients at a single center. Eur J Radiol 2012; 81 (10) 2495-2499
    CrossrefPubMedGoogle Scholar
  • 51 Stigliano R, Marelli L, Yu D, Davies N, Patch D, Burroughs AK. Seeding following percutaneous diagnostic and therapeutic approaches for hepatocellular carcinoma. What is the risk and the outcome? Seeding risk for percutaneous approach of HCC. Cancer Treat Rev 2007; 33 (05) 437-447
    CrossrefPubMedGoogle Scholar
  • 52 Kei SK, Rhim H, Choi D, Lee WJ, Lim HK, Kim YS. Local tumor progression after radiofrequency ablation of liver tumors: analysis of morphologic pattern and site of recurrence. AJR Am J Roentgenol 2008; 190 (06) 1544-1551
    CrossrefPubMedGoogle Scholar
  • 53 Ni JY, Liu SS, Xu LF, Sun HL, Chen YT. Meta-analysis of radiofrequency ablation in combination with transarterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol 2013; 19 (24) 3872-3882
    CrossrefPubMedGoogle Scholar
  • 54 Vouche M, Habib A, Ward TJ. et al. Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatology 2014; 60 (01) 192-201
    CrossrefPubMedGoogle Scholar
  • 55 Mazzaferro V, Sposito C, Bhoori S. et al. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology 2013; 57 (05) 1826-1837
    CrossrefPubMedGoogle Scholar
  • 56 Padia SA, Kwan SW, Roudsari B, Monsky WL, Coveler A, Harris WP. Superselective yttrium-90 radioembolization for hepatocellular carcinoma yields high response rates with minimal toxicity. J Vasc Interv Radiol 2014; 25 (07) 1067-1073
    CrossrefPubMedGoogle Scholar
  • 57 Padia SA, Johnson GE, Horton KJ. et al. Segmental yttrium-90 radioembolization versus segmental chemoembolization for localized hepatocellular carcinoma: results of a single-center, retrospective, propensity score-matched study. J Vasc Interv Radiol 2017; 28 (06) 777-785.e1
    CrossrefPubMedGoogle Scholar
  • 58 Biederman DM, Titano JJ, Bishay VL. et al. Radiation segmentectomy versus TACE combined with microwave ablation for unresectable solitary hepatocellular carcinoma up to 3 cm: a propensity score matching study. Radiology 2017; 283 (03) 895-905
    CrossrefPubMedGoogle Scholar
  • 59 Lewandowski RJ, Gabr A, Abouchaleh N. et al. Radiation segmentectomy: potential curative therapy for early hepatocellular carcinoma. Radiology 2018; 287 (03) 1050-1058
    CrossrefPubMedGoogle Scholar
  • 60 Varela M, Real MI, Burrel M. et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007; 46 (03) 474-481
    CrossrefPubMedGoogle Scholar
  • 61 Hong K, Khwaja A, Liapi E, Torbenson MS, Georgiades CS, Geschwind JF. New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Clin Cancer Res 2006; 12 (08) 2563-2567
    CrossrefPubMedGoogle Scholar
  • 62 Lewis AL, Taylor RR, Hall B, Gonzalez MV, Willis SL, Stratford PW. Pharmacokinetic and safety study of doxorubicin-eluting beads in a porcine model of hepatic arterial embolization. J Vasc Interv Radiol 2006; 17 (08) 1335-1343
    CrossrefPubMedGoogle Scholar
  • 63 Lammer J, Malagari K, Vogl T. et al; PRECISION V Investigators. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010; 33 (01) 41-52
    CrossrefPubMedGoogle Scholar
  • 64 Golfieri R, Giampalma E, Renzulli M. et al; PRECISION ITALIA Study Group. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer 2014; 111 (02) 255-264
    CrossrefPubMedGoogle Scholar
  • 65 Burrel M, Reig M, Forner A. et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using drug eluting beads. Implications for clinical practice and trial design. J Hepatol 2012; 56 (06) 1330-1335
    CrossrefPubMedGoogle Scholar